Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Yi-Long Lung Cancer Wu, Caicun Zhou, Chengping Hu et al. · The Lancet Oncology · 2014

Cited by 1,975 works. doi:10.1016/s1470-2045(13)70604-1

Authors

References